UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lecanemab in Early Alzheimer’s Disease

The New England journal of medicine, 2023-01, Vol.388 (1), p.9-21

2023

Volltextzugriff (PDF)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2021-04, Vol.13 (1), p.80-14, Article 80

2021

Volltextzugriff (PDF)

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Alzheimer's research & therapy, 2022-12, Vol.14 (1), p.191-191, Article 191

2022

Volltextzugriff (PDF)

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Alzheimer's & dementia, 2023-04, Vol.19 (4), p.1227-1233

2023

Volltextzugriff (PDF)

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies

Epilepsia (Copenhagen), 2013-08, Vol.54 (8), p.1481-1489

2013

Volltextzugriff (PDF)

Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations

The journal of pain, 2008-02, Vol.9 (2), p.105-121

2008

Volltextzugriff (PDF)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2023-01, Vol.9 (1), p.e12377-n/a

2023

Volltextzugriff (PDF)

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease

Alzheimer's research & therapy, 2022-12, Vol.14 (1), p.182-9, Article 182

2022

Volltextzugriff (PDF)

Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

Alzheimer's & dementia, 2024-08, Vol.20 (8), p.5617-5628

2024

Volltextzugriff (PDF)

Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studies

Epilepsia (Copenhagen), 2014-03, Vol.55 (3), p.423-431

2014

Volltextzugriff (PDF)

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

Pain (Amsterdam), 2003-12, Vol.106 (3), p.337-345

2003

Volltextzugriff (PDF)

Alzheimer's disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla)

Journal of comparative neurology (1911), 2013-12, Vol.521 (18), p.4318-4338

2013

Volltextzugriff (PDF)

Updated safety results from phase 3 lecanemab study in early Alzheimer's disease

Alzheimer's research & therapy, 2024-05, Vol.16 (1), p.105-12, Article 105

2024

Volltextzugriff (PDF)

Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2024-07, Vol.16 (3), p.e12621-n/a

2024

Volltextzugriff (PDF)

Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease

Alzheimer's research & therapy, 2024-07, Vol.16 (1), p.159-4, Article 159

2024

Volltextzugriff (PDF)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2022-05, Vol.14 (1), p.70-70, Article 70

2022

Volltextzugriff (PDF)

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial

JAMA network open, 2023-04, Vol.6 (4), p.e237230-e237230

2023

Volltextzugriff (PDF)

The β-Secretase BACE1 in Alzheimer’s Disease

Biological psychiatry (1969), 2021-04, Vol.89 (8), p.745-756

2021

Volltextzugriff (PDF)

Impact of Clinical Subgroup and Baseline Amyloid PET Centiloid Levels on Occurrence of ARIA in the Lecanemab Phase 3 Clarity AD Study in Early Alzheimer’s Disease (P1-9.007)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

An Industry Perspective: Future of Anti-Amyloid Trials

The Journal of Prevention of Alzheimer's Disease, 2020-03, Vol.7 (3), p.142-143

Kramer, Lynn D.

2020

Volltextzugriff (PDF)

Lecanemab phase 3 clarity AD trial: ARIA with the use of antiplatelets or anticoagulants in early Alzheimer's disease

Journal of the neurological sciences, 2023-12, Vol.455, p.121400, Article 121400

2023

Volltextzugriff (PDF)

Isolated ARIA-H in patients treated with lecanemab in the phase 3 clarity AD study in early Alzheimer's disease

Journal of the neurological sciences, 2023-12, Vol.455, p.121401, Article 121401

2023

Volltextzugriff (PDF)

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease

Annals of neurology, 2024-02, Vol.95 (2), p.288-298

2024

Volltextzugriff (PDF)

Predicting clinical progression trajectories of early Alzheimer's disease patients

Alzheimer's & dementia, 2024-03, Vol.20 (3), p.1725-1738

2024

Volltextzugriff (PDF)

1 – 25 von 284

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(225)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(284)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Lecanemab in Early Alzheimer’s Disease

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies

Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease

Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studies

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

Alzheimer's disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla)

Updated safety results from phase 3 lecanemab study in early Alzheimer's disease

Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment

Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

The β-Secretase BACE1 in Alzheimer’s Disease

Impact of Clinical Subgroup and Baseline Amyloid PET Centiloid Levels on Occurrence of ARIA in the Lecanemab Phase 3 Clarity AD Study in Early Alzheimer’s Disease (P1-9.007)

An Industry Perspective: Future of Anti-Amyloid Trials

Lecanemab phase 3 clarity AD trial: ARIA with the use of antiplatelets or anticoagulants in early Alzheimer's disease

Isolated ARIA-H in patients treated with lecanemab in the phase 3 clarity AD study in early Alzheimer's disease

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease

Predicting clinical progression trajectories of early Alzheimer's disease patients

Suchergebnisse filtern